Clinical Trials

Prostate Adenocarcinoma

NCT06022822 2026-04-13

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

90 enrolled

Phase 2 Active not recruiting

Prostate Adenocarcinoma

NCT03361735 2026-04-09

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled 10 charts

Phase 3 Active not recruiting

Prostate Adenocarcinoma

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

Prostate Adenocarcinoma

NCT06798558 2026-03-23

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

54 enrolled

Prostate Adenocarcinoma

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT06654336 2026-03-13

RATIONAL

162 enrolled

Prostate Adenocarcinoma

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Completed

11 enrolled 13 charts

Phase 1 Active not recruiting

Prostate Adenocarcinoma

NCT04943536 2026-02-27

BiolenRT

20 enrolled

Prostate Adenocarcinoma

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Phase 1 Recruiting

56 enrolled

Prostate Adenocarcinoma

NCT04704505 2026-02-06

BAT-RAD

47 enrolled

Prostate Adenocarcinoma

NCT06470750 2026-01-20

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Recruiting

77 enrolled

Prostate Adenocarcinoma

NCT04384770 2025-12-22

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

Active not recruiting

179 enrolled

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Prostate Adenocarcinoma

NCT05998278 2025-12-18

Personalized Optimization of Systematic Prostate Biopsy

Phase NA Recruiting

330 enrolled

Prostate Adenocarcinoma

NCT04543903 2025-12-02

Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

1 enrolled

Phase 2 Not yet recruiting

Prostate Adenocarcinoma

NCT07251829 2025-11-26

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

35 enrolled

Prostate Adenocarcinoma

NCT03860961 2025-11-03

Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy

550 enrolled 13 charts

Prostate Adenocarcinoma

NCT06499870 2025-10-21

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

50 enrolled

Phase NA Not yet recruiting

Prostate Adenocarcinoma

NCT07210502 2025-10-07

LDR BURST

220 enrolled

Prostate Adenocarcinoma

NCT01352429 2025-07-17

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

Active not recruiting

303 enrolled

Phase 2 Active not recruiting

Prostate Adenocarcinoma

NCT04743934 2025-05-04

RAD 2003

44 enrolled

Prostate Adenocarcinoma

NCT05665738 2025-04-29

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Phase NA Recruiting

17 enrolled

Prostate Adenocarcinoma

NCT03654638 2025-04-04

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Phase 2 Completed

25 enrolled

Prostate Adenocarcinoma

NCT02254746 2025-02-14

A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer

27 enrolled

Prostate Adenocarcinoma

NCT06736054 2024-12-16

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

Phase 1 Recruiting

8 enrolled

Phase 2 Active not recruiting

Prostate Adenocarcinoma

NCT03762759 2024-05-17

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

140 enrolled

Phase NA Not yet recruiting

Prostate Adenocarcinoma

NCT06387238 2024-04-29

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

150 enrolled

Prostate Adenocarcinoma

NCT05919524 2023-09-26

SAFO

Phase NA Unknown

27 enrolled

Prostate Adenocarcinoma

NCT02624518 2023-04-10

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Phase 2/3 Completed

122 enrolled 8 charts

Prostate Adenocarcinoma

NCT02721979 2023-02-09

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Phase 2 Terminated

24 enrolled 16 charts

Prostate Adenocarcinoma

NCT00887432 2021-10-26

Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

132 enrolled 11 charts

Prostate Adenocarcinoma

NCT04020094 2021-09-22

AtezoVax

Phase 2 Withdrawn

Prostate Adenocarcinoma

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Phase 1 Terminated

6 enrolled

Prostate Adenocarcinoma

NCT02031328 2020-11-24

2STAR

Phase 1/2 Unknown

30 enrolled

Prostate Adenocarcinoma

NCT02175212 2020-11-20

AADLPC

Phase 3 Completed

362 enrolled 17 charts

Prostate Adenocarcinoma

NCT03780023 2020-10-28

CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients

Completed

5 enrolled

Prostate Adenocarcinoma

NCT02168062 2020-07-23

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Phase 2 Terminated

57 enrolled 27 charts

Prostate Adenocarcinoma

NCT03285815 2017-09-18

Prostate Cancer - Localized Adenocarcinoma Proton Therapy

Phase NA Unknown

156 enrolled

Prostate Adenocarcinoma

NCT01219790 2016-04-19

GEMO

Phase 1 Completed

30 enrolled

Prostate Adenocarcinoma

NCT00183924 2014-05-22

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

Phase 2 Completed

20 enrolled